Nuvig Therapeutics
Vision
Rebalancing immune function for chronic inflammatory and autoimmune diseases
Approach
Nuvig aims to bring innovative and transformational therapies to patients with chronic autoimmune diseases, via induction of mechanisms that restore immune homeostasis. Their first product candidate is a recombinant engineered Fc fragment that selectively activates a class of immune regulatory receptors that are naturally involved in rebalancing immune function following inflammation. Additional efforts are focused on engineering full-length therapeutic antibodies to maximize their ability to control aggressive autoimmune diseases.
Nuvig Therapeutics is addressing
CEO:
Pamela Conley, Ph.D.
Founders:
Pamela Conley, Ph.D.
Greg Coffey, Ph.D.
First investment:
July 2024